Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices Agency). The review is expected to last approximately a year.